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Abstract: Granulocyte-monocyte colony stimulating factor (GM-CSF) is used as an adjuvant in
various clinical and preclinical studies with contradictory results. These were attributed to opposing
effects of GM-CSF on the immune or myeloid systems of the treated patients or to lack of optimal
dosing regimens. The results of the present study point to inter-tumor heterogeneity as a possible
mechanism accounting for the contrasting responses to GM-CSF incorporating therapies. Employing
xenograft models of human melanomas in nude mice developed in our lab, we detected differential
functional responses of melanomas from different patients to GM-CSF both in vitro as well as in vivo.
Whereas cells of one melanoma acquired pro metastatic features following exposure to GM-CSF,
cells from another melanoma either did not respond or became less malignant. We propose that
inter-melanoma heterogeneity as manifested by differential responses of melanoma cells (and perhaps
also of other tumor) to GM-CSF may be developed into a predictive marker providing a tool to
segregate melanoma patients who will benefit from GM-CSF therapy from those who will not.
Keywords: GM-CSF; melanoma; brain metastasis; metastatic microenvironment

1. Introduction
Brain metastasis frequently appears in patients with lung and breast cancer as well as in melanoma
patients. Due to limited and usually non-effective treatment options, brain metastasis is associated
with poor survival and therefore constitutes an unmet clinical challenge [1,2]. In melanoma patients,
metastasis occurs relatively early in the disease and quite frequently [1]. Patients diagnosed with brain
metastasis have a short overall survival [3] and systemic therapeutic options for such patients are poor
and only beneficial in a limited group of patients [4].
The brain microenvironment is unique with respect to anatomy, resident cells (e.g., astrocytes,
microglia), molecular milieu and the immune landscape [5,6].
Tumor cells that disseminated to the brain microenvironment engage in a cross talk with its
components thereby acquiring a phenotype which is adapted to this microenvironment. The brain-invading
cells in turn, contribute to the remodeling of the brain microenvironment and its establishment as a
hospitable accommodation.
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The interactions of the brain-metastasizing cells with brain microenvironmental cells (BMC) may
lead either to further metastatic progression or to the elimination of metastasis [1,7–9].
Elucidating the pathways leading to metastatic progression or to its inhibition is an
essential pre-requisite for the identification of new therapeutic targets and of novel anti-metastatic
treatment modalities.
Metastasis (including brain metastasis) can be driven or inhibited by three major types of
signaling factors—tumor-intrinsic factors, microenvironmental factors and downstream factors.
The downstream factors are generated by interactions between the metastasizing tumor cells and the
metastatic microenvironment.
To approach the identification of drivers and inhibitors of melanoma brain metastasis (MBM)
we developed a xenograft model of human MBM in nude mice. Local (cutaneous) tumor and brain
metastatic variants were developed from single human melanomas. Each pair of variants originated
thus from an identical genetic lineage [10]. Comparing transcriptomic [10], proteomic [11] and
epigenomic [12] profiles of these variants, we identified and characterized a number of tumor-intrinsic
and microenvironmental signaling factors as well as downstream factors. These three types of factors
were involved in driving or inhibiting MBM formation, survival and preservation [7–10,13–18].
In the present study we explored, further, the functional significance of interactions between
brain-metastasizing melanoma cells and microenvironmental cells of the brain. We found that the levels
of granulocyte-monocyte colony stimulating factor (GM-CSF) in the metastatic microenvironment
(MME) of the brain were upregulated as a result of these interactions. This cytokine promoted or
restrained the progression of melanoma cells towards metastasis.
2. Materials and Methods
2.1. Cell Culture
The development, culturing and maintenance of human cutaneous melanoma variants YDFR.C
and DP.C and human MBM variants YDFR.CB3 and DP.CB2 were previously described [10,13].
The original cell lines from which these variants were established were kindly provided by Michael
Micksche (YDFR, Department of Applied and Experimental Oncology, Vienna University, Austria)
and Dr. Dave S.B. Hoon (DP-0574-Me, Department of Translational Molecular Medicine, John Wayne
Cancer Institute, Saint John’s Health Center Providence Health Systems, Santa Monica, CA, USA).
mCherry-expressing melanoma cells (YDFR.CB3 and DP.CB2) harboring the pQCXIP-mCherry plasmid
were constructed, cultured and maintained as previously described [9]. Immortalized human brain
microvascular endothelial cells (hCMEC/D3, BEC) were kindly provided by Dr. Clara Nahmias and
Prof. Pierre-Olivier Couraud (Inserm, U1016, Institute Cochin, Paris, France) and were maintained
as previously described [19]. Human astrocytes (HA; Cat# 1800, lot# 9063, ScienCell Research
Laboratories, Carlsbad, CA, USA) were maintained as previously described [16]. Immortalized human
microglia-SV40 cell line (RRID: CVCL_YN91, Cat# T0251, lot# RZ825016, ABM, Milton, ON, Canada)
was maintained as previously described [14]. The identity of all cell lines used was authenticated
using STR. 0.5% FCS supplemented medium was used for starvation in all the experiments. Cells were
routinely cultured in humidified air with 5% CO2 at 37 ◦ C.
2.2. Preparation of Melanoma- or Brain Cell-Conditioned Medium
Melanoma cells or brain cells (microglia, brain endothelial cells (BEC) and astrocytes) were
cultured for 24 h, then starved for additional 24 h. Melanoma-conditioned medium (MCM),
brain endothelial cell-conditioned medium (BEC-CM), microglia-conditioned medium (MG-CM)
or astrocyte-conditioned medium (HA-CM) was collected, centrifuged for 5 min at 1400 rpm and
filtered (0.45 µm, Whatman GmbH, Dassel, Germany).
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2.3. ELISA Assay
For the estimation of basal GM-CSF levels, cells were plated and grown in 0.5% FCS supplemented
starvation medium for 24 h. For CM-treatments, cells were plated and stimulated with CM or with
starvation media as control for 4 h, then washed and starved for 24 h. For cytokine treatments,
cells were stimulated with recombinant cytokines for 24 h. Alternatively, cells were co-stimulated
with CM and cytokines for 4 h, then starved for 24 h. Cytokines used were—recombinant human
interleukin-1α (hIL-1α, 1–50 ng/mL) and recombinant human tumor necrosis factor-α (rhTNF-α,
1−50 ng/mL) (PeproTech, Rocky Hill, NJ, USA).
The supernatants were then collected, centrifuged, filtered and 15-fold (melanoma supernatants)
or 30-fold (brain cell supernatants) concentrated at 4000× g using Amicon®Ultra-15 centrifugal filter
units (Merck Millipore, Burlington, MA, USA) for 1 h. The fraction (MW > 3 kDa) was used to determine
the extracellular levels of GM-CSF by ELISA according to manufacture instructions using the human
GM-CSF DuoSet (R&D systems, Minneapolis, MN, USA).
2.4. Downregulation of GM-CSF Expression
The downregulation of GM-CSF was constructed using pGIPZ vectors (Thermo Fisher Scientific,
ABgene, Germany) containing shRNA sequences targeting human CSF2 mRNA (NM_000758.4).
For the preparation of melanoma GM-CSF knocked-down cells, a combination of two vectors was used
(V3LHS_374948 and V3LHS_374949) to transfect YDFR.CB3 and DP.CB2 cells (shCSF2). The cells were
produced as previously described [13]. A sh-non-silencing pGIPZ vector (RHS4531) was used as a
negative control (shControl). All plasmids used were containing a GFP-tag. Transfected cells were
selected using 1 µg/mL puromycin (InVivoGen, San Diego, CA, USA).
2.5. Adhesion to Brain Endothelial Cells
Adhesion of melanoma cells to BEC was performed as previously described [16] with minor
modification. Briefly, the cells were stimulated with 10 ng/mL recombinant human GM-CSF (rhGM-CSF)
(PeproTech, Rocky Hill, NJ, USA) in starvation medium or cultured in starvation medium as
control for 24 h prior to the incubation of melanoma cells upon the BEC monolayer. Adhesion
of mCherry-expressing cells was measured at wavelength of 590/645. To obtain the percentage of
adherent cells, the optical density (OD) of the adherent cells was divided by the OD of the total
cells plated.
2.6. Transendothelial Migration Through a Blood-Brain Barrier Model
Transendothelial migration assays were performed as previously described [13] with modifications.
For mCherry-melanoma transendothelial migration assays, 1 × 105 cells were loaded onto BEC
monolayer-seeded transwells (8 µm; Corning Costar Corp.) with or without 10 ng/mL rhGM-CSF.
Alternatively, melanoma or BEC cells were stimulated with rhGM-CSF (separately) for 24 h prior to the
loading of melanoma onto BEC monolayer-seeded transwells. Cells were allowed to migrate for 24 h.
For CSF2-silenced melanoma migration assays, 1 × 105 cells were loaded onto BEC monolayer-seeded
transwells and allowed to migrate for 24 h. Fixation, imaging of transwells and respective biostatistical
analysis was performed as previously described [13].
2.7. Immunodetection of Proteins by Western Blot
BEC were plated and stimulated with 30 ng/mL rhGM-CSF for 2, 6, 24 or 48 h. As control,
cells were grown without rhGM-CSF for an equal amount of time. The cells were washed twice with
ice-cold physiological phosphate-buffered saline (PBS) and lysed as previously described [17]. Proteins
were separated on 4–12% Bis–Tris gels (Thermo Fisher Scientific, ABgene, Germany) and transferred
onto nitrocellulose membranes. The membranes were blocked at room temperature with 3% BSA
diluted in TBS–Tween for 1 h. The following primary Abs were used—anti-claudin-5 (A-12) Ab (Cat#
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sc-374221, RRID:AB_10988234, Santa Cruz Biotechnology, Dallas, TX, USA), anti-occludin (E5) Ab
(Cat# sc-133256, RRID:AB_2156317, Santa Cruz Biotechnology), anti-β-tubulin Ab - Loading Control
(Cat# ab-6046, RRID:AB_2210370, Abcam, Cambridge, UK) and anti-zonula occludens-1 (ZO-1) (H-300)
Ab (sc-10804, RRID:AB_2205514, Santa Cruz Biotechnology, Dallas, TX, USA). As secondary Abs,
horseradish peroxidase-conjugated donkey anti-mouse Ab or goat anti-rabbit Ab (1:10,000, Jackson
ImmunoResearch Laboratories, West Grove, PA, USA) were used. The gel bands were visualized by
chemiluminescence ECL reactions (Merck Millipore). The processing of bands intensity was performed
with ImageQuant TL Version 8.1 (GE Healthcare Life Sciences, Chicago, IL, USA). Each experiment
was repeated 3–5 times.
2.8. Animals
Male athymic nude mice (BALB/c background) were purchased from Harlan Laboratories Limited
(Jerusalem, Israel). The mice were housed and maintained in laminar flow cabinets under specific
pathogen-free conditions in the animal quarters of Tel-Aviv University and in accordance with current
regulations and standards of the Tel-Aviv University Institutional Animal Care and Use Committee.
The project identification code: 04-16-044; date of approval: 11/07/2016. The mice were used when they
were 7–8 weeks old.
2.9. Orthotopic Inoculation of Tumor Cells
To generate subcutaneous (SC) tumors, mice (n = 8 in each group) were inoculated SC with
1 × 106 melanoma cells in 100 µL of 5% FCS RPMI-1640 medium as previously described [10].
To test the tumorigenic properties of derived cell lines, SC tumors were measured once a
week using a caliper. Tumor volume was obtained by the ellipsoid volume calculation formula
Tumor volume = 0.5 × (length × width × width) as previously described [20].
2.10. Intracardiac Inoculation of Tumor Cells
For intracardiac (IC) inoculation, cells were harvested by trypsinization and transferred into
RPMI-1640 medium supplemented with 5% FCS.
Prior to IC inoculation, nude mice (n = 8 in each group) were anesthetized by ketamine
(100 mg/kg body mass) and xylazine (10 mg/kg body mass) (Kepro, Deventer, The Netherlands)
administered intraperitoneally. Using a small animal ultrasound device (Vevo 770 High-Resolution
In Vivo Micro-Imaging System; VisualSonics, Toronto, Canada), 5 × 105 cells in 50 µL of 5% FCS
RPMI-1640 medium were inoculated into the left ventricle of the heart, using a 29-gauge needle.
Mice were sacrificed, brains were dissected out and immediately cryopreserved at −70 ◦ C until used
for RNA extraction.
2.11. RNA Preparation and Reverse Transcription Droplet Digital PCR (RT-ddPCR)
Total cellular RNA was extracted from mice brains using EZ-RNA Total RNA Isolation Kit
(Biological Industries, Kibbutz Beit Haemek, Israel). RNA concentrations were determined by the
absorbance at 260 nm and quality control standards were A260/A280 = 1.8–2.0. 1 µL of each RNA sample
was used for cDNA synthesis using the qScript cDNA Synthesis Kit (Quantabio, Beverly, MA, USA)
according to the manufacturer’s instructions. The detection of human cDNA was conducted with QX200
ddPCR System (BioRad, Philadelphia, PA, USA). The reaction mix was prepared with ddPCR Supermix
for Probes (BioRad, Philadelphia, PA, USA), 1 µL of cDNA and probe assay consisting of unlabeled PCR
primers and a labeled fluorescent probe. The following primers were used—β2 microglobulin (β2m),
Human, tagged with FAM (unique Assay ID: dHsaCPE5053100, BioRad, Philadelphia, PA, USA) and
β2m, Mouse, tagged with HEX (unique Assay ID: dMmuCPE5124781, BioRad, Philadelphia, PA, USA).
Each run included a positive control (cDNA from human melanoma cell culture), negative control
(cDNA from naïve mouse brain) and no template control. Droplet generation, transfer of droplets,
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plate sealing and PCR reaction conditions were as described by the manufacturer. The processing of
PCR products was performed with QuantaSoft Version 1.7.4 (BioRad, Philadelphia, PA, USA).
2.12. mRNA Sequencing Analysis
Cells were plated and grown in starvation media for 24 h with or without 10 ng/mL rhGM-CSF.
Plates were washed with cold PBS and RNA was extracted using miRNeasy mini kit (Qiagen, Valencia,
CA, USA). Concentration of purified total RNA was measured using the Quant-iT RiboGreen RNA
assay (Life Technologies, Carlsbad, CA, USA) and RNA quality was assessed by the RNA ScreenTape
assay on the Agilent TapeStation 2200 (Agilent Technologies, Santa Clara, CA, USA). Using 1ug of
high quality (RIN > 7.0) total RNA, mRNA libraries were prepared from 3 independent repeats for
each treatment with the NEXTflex Rapid Directional mRNA-Seq Kit (Bioo Scientific, Austin, TX,
USA). Quality and quantity of final libraries were assessed by High Sensitivity D1000 assay (Agilent
Technologies) and Qubit dsDNA HS assay (Life Technologies, Carlsbad, CA, USA), respectively.
Libraries were pooled and sequenced on an Illumina NextSeq 550 (Illumina Inc, San Diego, CA, USA)
using 76bp paired-end reads.
Raw RNA sequencing reads were checked for overall quality and filtered for adapter
contamination using Trimmomatic (version 0.36) [21]. The filtered reads were then mapped to
the GENCODE comprehensive gene annotation reference set (version 19) using the STAR aligner
(version 2.4.2a) [22] with default parameters. Read counts for each feature were generated using
the “–quantModeGeneCounts” function in STAR. Significantly differentially expressed genes were
identified using ANOVA with a significance threshold of fold change (FC) < −1.5 or FC > 1.5 and
p-value ≤ 0.05.
2.13. Biostatistical Analysis
Data were analyzed using Student’s t test and considered significant at p-values ≤ 0.05. Bar graphs
represent mean and standard deviation (SD) or standard error of the mean (SEM) across multiple
independent experimental repeats.
3. Results
3.1. Melanoma-Derived Soluble Factors (MCM) Enhance GM-CSF Secretion from Brain
Microenvironmental Cells
GM-CSF is secreted from unstimulated BEC and from astrocytes but not from microglia (Figure 1a).
Soluble factors derived from YDFR.CB3 cells, the brain metastatic variant of the human YDFR melanoma
cell line [10], significantly increased GM-CSF secretion from BEC and astrocytes by 35% and 40%,
respectively (Figure 1b). Soluble factors derived from DP.CB2 cells, the brain metastatic variant of the
human DP-0574-Me melanoma cell line [13], significantly increased GM-CSF secretion from astrocytes
by 45% but did not affect GM-CSF secretion from BEC. Microglia treated with YDFR.CB3 or with
DP.CB2 MCM did not secrete GM-CSF.
3.2. The Effects of GM-CSF on Brain Endothelial Cells
Tumor-endothelium interactions are pivotal in brain metastasis formation. We therefore evaluated
the effects of GM-CSF on the gene expression profile of BEC and on the integrity of several of their
tight junction (TJ) components being highly involved in transendothelial migration.
3.2.1. GM-CSF Alters the Gene Expression Profile of BEC
We compared the gene expression profile of rhGM-CSF-activated BEC to that of untreated BEC.
The results (Table 1) indicated that in general GM-CSF-activated genes promote metastasis progression
by positively regulating transendothelial migration and angiogenesis.
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Angiogenesis related genes
1.
2.
3.

4.

The upregulated gene carbonic anhydrase 9 (CA9, FC = 4.18) induces endothelial migration
and angiogenesis in tumors [27].
The upregulated gene serum/glucocorticoid regulated kinase 2 (SGK1, FC = 2.84) is required
for endothelial cell migration and angiogenesis [28].
The downregulated gene ephrin B3 (EFNB3, FC = −3.99) supports endothelial cell survival
and its silencing decreases tumor vascularization and growth in a glioblastoma xenograft
model [29].
The downregulated gene RUNX family transcription factor 3 (RUNX3, FC = −2.33)
contributes to endothelial-to-mesenchymal transition and endothelial cell dysfunction.
RUNX3 downregulation reduced endothelial cell migration and promoted angiogenesis [30].
Table 1. Differentially expressed genes in rhGM-CSF-stimulated BEC vs. untreated control cells.

Gene Symbol

Gene Name

FC

p-Value

Upregulated
LYPD3

LY6/PLAUR domain containing 3

7.62

0.000944

HPD

4-hydroxyphenylpyruvate dioxygenase

5.26

0.000679

CA9

carbonic anhydrase 9

4.18

7.42 × 10−5

MIR3124

microRNA 3124

4.02

5.36 × 10−6

PNPLA1

patatin like phospholipase domain containing 1

3.84

7.94 × 10−6

CGB7

chorionic gonadotropin subunit beta 7

3.71

0.000861

PCDHGA7

protocadherin gamma subfamily A, 7

3.66

0.000385

LINC02310

long intergenic non-protein coding RNA 2310

3.63

0.000158

ADCY10

adenylate cyclase 10

3.01

1.1 × 10−5

DIPK2B

divergent protein kinase domain 2B

2.94

2.01 × 10−5

SGK2

serum/glucocorticoid regulated kinase 2

2.84

0.000594

GLS2

glutaminase 2

2.82

0.000387

CASKIN1

CASK interacting protein 1

2.62

0.000489

LY6G5C

lymphocyte antigen 6 family member G5C

2.42

0.000438

PRSS27

serine protease 27

2.40

0.000651

ARHGAP40

Rho GTPase activating protein 40

2.38

0.00044

ARHGAP9

Rho GTPase activating protein 9

2.15

0.000554

SLC17A7

solute carrier family 17 member 7

2.12

0.00088

PDF

peptide deformylase, mitochondrial

2.07

0.000363

RBM44

RNA binding motif protein 44

2.02

0.000415

ALLC

allantoicase

2.01

5.31 × 10−6

Downregulated
RAB11FIP4

RAB11 family interacting protein 4

−6.13

0.000349

CES4A

carboxylesterase 4A

−4.98

6.78 × 10−5

KHDRBS3

KH RNA binding domain containing, signal transduction associated 3

−4.41

0.000557

EFNB3

ephrin B3

−3.99

8.79 × 10−5

RPL21P28

ribosomal protein L21 pseudogene 28

−2.80

0.000986

LINC00954

long intergenic non-protein coding RNA 954

−2.71

0.000508
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Gene Symbol

Gene Name

FC

p-Value

IRS2

insulin receptor substrate 2

−2.53

0.000306

TSHZ3

teashirt zinc finger homeobox 3

−2.51

0.000497

CSGALNACT1

chondroitin sulfate N-acetylgalactosaminyltransferase 1

−2.41

7.75 × 10−5

KREMEN1

kringle containing transmembrane protein 1

−2.37

0.000685

IL37

interleukin 37

−2.36

2 × 10−6

RUNX3

RUNX family transcription factor 3

−2.33

0.000937

ZFP37

ZFP37 zinc finger protein

−2.06

0.000857

List of 34 down-regulated or up-regulated genes (fold change (FC) < −1.5 or FC > 1.5 and p-value ≤ 0.05) in brain
endothelial cells exposed to 10 ng/mL rhGM-CSF, compared to untreated cells.

3.2.2. GM-CSF Down-Regulates the Expression of the Endothelial Tight Junction Proteins Claudin-5
and Zonula Occludens-1
TJs regulate permeability of the blood-brain barrier (BBB) [31]. In light of findings that
GM-CSF modulates TJ components claudin-5 [32] and zonula occludens-1 (ZO-1) [33] thereby altering
transendothelial migration of mouse monocytes, we asked if human GM-CSF would also induce
similar effects in human brain endothelial cells. rhGM-CSF was added to cultured BEC for 2, 6, 24 and
48 h. A significant decrease in claudin-5 levels in GM-CSF treated BEC was observed 24 and 48 h post
stimulation (Figure 1c). Similarly, expression levels of ZO-1 decreased in GM-CSF treated BEC 6 h
post stimulation (Figure 1d). GM-CSF did not alter the levels of another TJ related protein, occludin
(data not shown). These results suggest that GM-CSF has the capacity to control the permeability
of melanoma cells through the BBB by downregulating the expression of TJ components claudin-5
and ZO-1.
3.3. GM-CSF is Secreted from Human Melanoma Cells
Cell lines derived from 2 different melanomas YDFR and DP-0574-Me (DP) were employed in
this study. Both local (cutaneous) and brain metastatic variants from these cell lines (YDFR.C, DP.C
and YDFR.CB3, DP.CB2 respectively) secreted GM-CSF but in different amounts (Figure 2a,b). The
overall GM-CSF secretion from the DP variants was higher than that secreted from the YDFR variants.
The metastatic YDFR.CB3 cells secreted higher amounts of GM-CSF than the cutaneous YDFR.C cells.
The same trend was found for the DP cell line, as the metastatic DP.CB2 cells secreted higher amounts
Cells
9, x FOR
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9 of 17
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than
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increased GM-CSF secretion by 54%. Microglia-derived soluble factors did not alter GM-CSF
secretion
(Figure
2d). Differentially Influence GM-CSF Secretion from Melanoma Cells
3.5. IL-1α
and TNF-α
The expression of the inflammatory cytokines IL-1α and TNF-α increases significantly in CNS
pathologies [34,35]. Increased levels of these cytokines in the brain are associated with increased
BBB permeability [34]. In order to determine if these 2 cytokines play a regulatory role in GM-CSF
secretion from melanoma cells we treated YDFR.CB3 and DP.CB2 cells with rhIL-1α and rhTNF-α.
These cytokines strongly enhanced GM-CSF secretion from YDFR.CB3 and DP.CB2 cells (Figure 2e,f).
The enhancement of GM-CSF secretion from YDFR.CB3 cells by rhIL-1α or rhTNF-α treatment was
inhibited by ~20 % when melanoma cells were treated with rhIL-1α or rhTNF-α mixed with microglia
conditioned medium (Figure 2g,h). GM-CSF secretion from DP.CB2 cells following a co-incubation
with the two cytokines in combination with MG-CM was not measured since MG-CM did not affect
GM-CSF secretion from DP.CB2 cells. These results indicate that in addition to factors such as IL-1α or
TNF-α that stimulate the secretion of GM-CSF from melanoma cells, the microglial secretome contains
factors that inhibit GM-CSF secretion from melanoma cells.

microglia conditioned medium (Figure 2g,h). GM-CSF secretion from DP.CB2 cells following a
co-incubation with the two cytokines in combination with MG-CM was not measured since MG-CM
did not affect GM-CSF secretion from DP.CB2 cells. These results indicate that in addition to factors
such as IL-1α or TNF-α that stimulate the secretion of GM-CSF from melanoma cells, the microglial
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The impact of GM-CSF on transendothelial migration was investigated next. An experimental BBB
model consisting of cell-permeable transwells seeded with BEC was employed. The transmigration of
mCherry-expressing YDFR.CB3 and DP.CB2 cells through the BEC layer was evaluated in the presence
or absence of rhGM-CSF. Whereas GM-CSF enhanced the transmigration of the YDFR.CB3 cells it did
not enhance the transendothelial migration of DP.CB2 cells (Figure 4a,b).
To further validate these results, we generated GFP-expressing YDFR.CB3 and DP.CB2 cells
in which GM-CSF was silenced by specific shRNA (shCSF2). Control cells were infected with a
non-silencing shRNA (shControl). The plasmids used contained a GFP tag. GM-CSF silencing
did not affect cell viability (data not shown). These experiments supported the findings that
GM-CSF positively regulates the transendothelial migration of YDFR.CB3 cells; the transmigration
of YDFR.CB3-shCSF2 cells was reduced compared to control cells (Figure 4c). Similar experiments
performed with DP.CB2-shCSF2 cells yielded opposite results, as the transmigration of DP.CB2-shCSF2
cells was higher than that of the control cells (Figure 4d). In order to identify which of the two interacting
cells (melanoma or BEC) responded to GM-CSF under these conditions, mCherry-expressing YDFR.CB3
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To further validate these results, we generated GFP-expressing YDFR.CB3 and DP.CB2 cells in
which GM-CSF was silenced by specific shRNA (shCSF2). Control cells were infected with a
non-silencing shRNA (shControl). The plasmids used contained a GFP tag. GM-CSF silencing did

transmigration of YDFR.CB3 as well as DP.CB2 melanoma cells, the migration of pre-treated
melanoma cells through untreated BEC was similar to that of untreated control melanoma cells
(Figure 4e,f) These results indicate that GM-CSF may enhance the transendothelial migration of cells
originating in some melanomas by reprograming BEC. GM-CSF-mediated enhanced
transendothelial migration of melanoma cells occurs only through reprogrammed (but not naïve)
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We asked if expression levels of GM-CSF by melanoma cells affect the formation of brain metastasis.
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were sacrificed six weeks later. Quantification of human and mouse RNA in the brains was
mice inoculated with GM-CSF knocked-down YDFR.CB3 cells was lower than the median value of
human/mouse β2m mRNA expression in the brains of mice inoculated with YDFR.CB3 shControl cells
(0.758 vs 1.14). GM-CSF knock-down in DP.CB2 cells yielded opposite results. The median value of
human/mouse β2m mRNA expression in the brains in the group of mice inoculated with GM-CSF
silenced DP.CB2 cells was higher than the median value of human/mouse β2m mRNA expression in
the brains of mice inoculated with DP.CB2 shControl cells (4.14 vs 1.37). These results are compatible
with the tumorigenicity-modifying function of GM-CSF reported above. Taken together the results of
this study show (Table 2) that:
1.
2.

GM-CSF exerts regulatory functions on the metastatic microenvironment of the brain.
GM-CSF impacts differently the malignant phenotype of melanoma cells from different patients;
augmenting the malignancy of one melanoma while restraining the malignancy of another.
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Table 2. The impact of GM-CSF on the brain metastatic melanoma cells YDFR.CB3 and DP.CB2.

GM-CSF expression

in-vitro function of
GM-CSF

in-vivo function of
GM-CSF

YDFR.CB3

DP.CB2

Expression in cutaneous vs.
MBM 1 variants

Higher in the metastatic
variant

Higher in the metastatic
variant (NS 2 )

Expression in MG-CM 3 treated MBM

Down-regulation

Not altered

Expression in BEC-CM 4 treated MBM

Not altered

Down-regulation

Expression in HA-CM 5 treated MBM

Not altered

Up-regulation

IL-1α 6 treatment

Up-regulation

Up-regulation

TNF-α 7 treatment

Up-regulation

Up-regulation

IL-1α + MG-CM treatment

Down-regulation

NA 8

TNF-α + MG-CM treatment

Down-regulation

NA

Adhesion to BEC

Decreased

Not altered

TEM 9 in the presence of
rhGM-CSF 10

Increased

Not altered

TEM effect of shCSF2 11

Decreased

Increased

TEM MBM + rhGM-CSF

Not altered

Not altered

TEM BEC + rhGM-CSF

Increased

Increased

Tumorigenesis

Increased

Decreased

Brain metastasis

Increased

Decreased

Summary of the differential responses of brain metastatic melanoma cells YDFR.CB3 and DP.CB2 to GM-CSFmediated activation. 1 MBM: melanoma brain metastasis, 2 NS: not significant, 3 MG-CM: microglia-conditioned
medium, 4 BEC-CM: brain endothelial cell-conditioned medium, 5 HA-CM: human astrocyte-conditioned medium,
6 IL-1α: interleukin-1α, 7 TNF-α: tumor necrosis factor-α, 8 NA: not applicable, 9 TEM: transendothelial
migration, 10 rhGM-CSF: recombinant human granulocyte-macrophage colony-stimulating factor, 11 shCSF2:
shRNA targeting GM-CSF.

4. Discussion
GM-CSF, a hematopoietic cytokine, produced by T cells, macrophages and a variety of non-lymphoid/
myeloid stroma cells, is a key factor in the maturation, differentiation, proliferation and activation
of myeloid cells such as macrophages, granulocytes, dendritic cells and so forth. GM-CSF has
inflammatory and immune regulatory functions and as such is an essential constituent of various
immune responses [37].
GM-CSF being a crucial factor in anti-tumor immunity [38,39], is an important constituent of
various anti-cancer immunotherapy trials. Preclinical as well as clinical studies yielded beneficial
responses in certain populations of cancer patients or in experimental animals and harmful responses
in others [40,41].
Summarizing the state of the art regarding clinical trials in which GM-CSF has been used as an
adjuvant in many different clinical trial settings in melanoma patients, Hoeller noted that evidence for
clinical efficacy of GM-CSF is controversial and that the optimal treatment regimen and effectiveness
of such treatment in patients with advanced melanoma has to be worked out [42].
Studies performed in our lab aim to identify drivers or inhibitors of melanoma brain metastasis.
To reach this goal we analyze the interactions of brain-metastasizing melanoma cells with brain
microenvironmental cells [7–9]. The major conclusion derived from these studies was that the cross-talk
between brain-metastasizing melanoma cells and microenvironmental cells residing in the brain
determine metastasis formation in this organ [43].
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In the present study we found that melanoma-brain interactions impact the expression of GM-CSF
and its secretion from both the melanoma cells as well as brain cells.
GM-CSF altered the gene-expression profile of brain endothelial cells rendering them supportive
for metastatic progression. Indeed, GM-CSF downregulated the expression of TJ components thereby
increasing BBB permeability.
Microglia that did not secrete GM-CSF, did inhibit, to a certain extent its secretion from melanoma
cells showing that microglia cells are involved, indirectly, in establishing the microenvironmental levels
of this cytokine. Microglia-derived IL-1α and TNF-α were found to upregulate GM-CSF secretion
from melanoma cells. This demonstrates that microglia, like many other cells, secrete, simultaneously,
factors that may exert opposite effects on melanoma progression. The bioactivity of such a mixture of
agonists and antagonists is determined by a balance between the two. In this case microglia-derived
factors that inhibit GM-CSF secretion from melanoma cells were dominant.
A major result of this study is that melanoma cells from 2 different cell lines differed from each
other in their response to GM-CSF (Table 2). Whereas GM-CSF promoted the in vitro malignancy
phenotype and the in vivo local tumorigenicity and brain metastasis of YDFR.CB3 cells, it either did
not influence the malignancy of DP.CB2 cells or even reduced it.
These results may constitute a relevant example of inter-tumor heterogeneity [44] reported recently
by us to occur in melanoma cells derived from 4 individual melanoma patients [11]. Cutaneous
and brain metastatic variant pairs from these melanomas, sharing the same genetic ancestry, were
subjected to proteome profiling aiming to identify shared molecular pathways leading to brain
metastasis. This analysis, although revealing a large variety of proteins differentially expressed by
local and brain metastatic variants, did not identify any protein that characterizes the transition from
cutaneous melanoma to brain metastasis which is shared by the 4 melanomas. This inter-melanoma
heterogeneity may be the basis for the differential response of melanoma patients to GM-CSF-associated
therapy [42–46].
Intra-melanoma heterogeneity [47] may have also played a role in the opposing effects of GM-CSF
on the malignancy phenotype of the 2 melanoma cells investigated in the present study. The YDFR.CB3
population may be composed of a majority of cells responding by a heightened malignancy to GM-CSF
mediated signaling whereas the DP.CB2 population may be composed of a majority of cells which are
refractory to such signals. Genomic studies should provide the mechanisms underlying the contradictory
response of melanomas (increased or decreased malignancy) to GM-CSF-mediating signaling.
We hypothesize that patient-derived melanomas may express either the YDFR.CB3 or DP.CB2
phenotype with respect to genomic, transcriptomic and functional responses to GM-CSF.
In vitro responses of melanoma cells to GM-CSF may be developed to a predictive biomarker to
better assess the response of individual melanoma patients to GM-CSF treatment thereby providing a
tool to segregate melanoma patients who will benefit from GM-CSF therapy from those who will not.
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